To access this element change to forms mode OFF
Grant Award View - GA320160
MRFCRI - ADVANCELL ISOTOPES PTY LIMITED
GA ID:
GA320160
Agency:
Department of Health and Aged Care
Approval Date:
23-Apr-2023
Publish Date:
5-Jul-2023
Category:
Medical Research
Grant Term:
22-Jun-2023 to 6-Dec-2028
Value (AUD):
$10,741,495.60
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 22/23 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
MRFCRI - ADVANCELL ISOTOPES PTY LIMITED
Purpose:
Targeted Alpha Therapy (TAT) is an emerging cancer treatment used to selectively deliver alpha radiation directly to cancer cells. This is achieved using small molecule radioligands which specifically deliver the lethal payload of radiation directly to the tumour site and nowhere else in the body. The major challenge for widespread adoption of this therapy is the scalable manufacture of alpha emitting isotopes. AdvanCell has developed a Lead-212 isotope generator capable of providing a scalable supply of GMP alpha isotope which will led to the expansion and strengthening of Australias alpha radiopharmaceutical industry sector.
GO ID:
GO Title:
MRFF 2022 National Critical Research Infrastructure Grant Opportunity
Internal Reference ID:
MRFCRI000225
Selection Process:
Open Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
ADVANCELL ISOTOPES PTY LIMITED
Recipient ABN:
42 633 959 010
Grant Recipient Location
Suburb:
SYDNEY
Town/City:
SYDNEY
Postcode:
2000
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
4069
Country:
AUSTRALIA